Strength Training Plus Cardio Just Cut Diabetes Risk
A new meta-analysis published in Sports Medicine and reported by News-Medical.net found that combining strength training with aerobic exercise cuts Type 2 diabetes risk more than either modality alone. Across 35 studies and over 90,000 participants, the combination reduced Type 2 diabetes risk by 17–40% depending on dose, with the strongest effect at 150+ minutes […]
An Oral GLP-1 Just Hit 89% A1c Target
A new phase 2b trial of Eli Lilly’s investigational oral GLP-1 elecoglipron showed that up to 89.6% of participants with Type 2 diabetes reached an A1c of 7% or lower, compared with just 24.9% on placebo —and up to 72.3% achieved at least 5% weight loss versus 20.2% on placebo. The results, presented this week […]
Retatrutide Just Got Renal Data
Eli Lilly’s retatrutide — the triple-hormone receptor agonist that already made headlines in 2026 for its 2.0% A1c reduction and 16.8% body-weight loss in Type 2 diabetes — just published renal outcomes data in The New England Journal of Medicine. The ORBIT trial evaluated retatrutide in adults with Type 2 diabetes and chronic kidney disease, […]
The ADA’s Own Definition of Remission Just Hit a Wall
The American Diabetes Association’s own consensus definition of type 2 diabetes remission — HbA1c < 6.5% for at least 3 months, off all glucose-lowering medication — just turned five years old, and a growing body of 2026 evidence shows that the vast majority of patients on mainstream diabetes drugs never get close to meeting it. […]
Stanford Just Found Why GLP-1s Don’t Work for 1 in 10 People
Stanford researchers just published findings that roughly 1 in 10 people carry genetic variants that make GLP-1 receptor agonist drugs — Ozempic, Mounjaro, Wegovy — meaningfully less effective at lowering blood sugar. The Stanford Medicine News report describes a meta-analysis of three clinical trials showing that carriers of specific variants in the PAM gene reach […]
Generic Dapagliflozin Just Got Approved.
The FDA has approved generic versions of dapagliflozin, a workhorse Type 2 diabetes medication in the SGLT2 inhibitor class, and the coverage has been almost entirely about access. Lower cost. More refills. Fewer prior-authorization fights at the pharmacy counter. For the millions of adults in the US who take a daily SGLT2 inhibitor to lower […]
Lilly’s Oral GLP-1 Just Hit Its Numbers. It’s Still Not Reversal.
Eli Lilly’s oral GLP-1, orforglipron, just hit its primary endpoint in the first Phase 3 trial designed to support an FDA submission. The Lilly press release announced results from ACHIEVE-1, published in The New England Journal of Medicine, showing a 1.3%–1.6% A1c reduction and 6.8%–7.9% weight loss in adults with early Type 2 diabetes on […]
ADA 2026 Made Multimorbidity the Headline.
At the 2026 ADA Scientific Sessions in New Orleans, a team from Leicester launched a three-paper Lancet Series on cardiometabolic multimorbidity — and the agenda tells you exactly where the diabetes conversation is right now. What the Lancet Series Covers The Leicester/NIHR ARC East Midlands team presented three new papers in The Lancet on June […]
The ADA Just Rewrote Its Standards of Care. It Still Won’t Reverse Diabetes.
The most influential diabetes document in America just dropped. The American Diabetes Association’s 202 Standards of Care in Diabetes — published in December 2025 in Diabetes Care (Volume 49, Supplement 1) and now in effect across U.S. endocrinology practices — is the annual clinical playbook that 90%+ of American endocrinologists follow when treating Type 2 […]
Once-Weekly Insulin Is Here. It’s Still Not Reversal.
The FDA just approved the first once-weekly basal insulin for Type 2 diabetes — Novo Nordisk’s Awiqli, greenlit on March 26, 2026 per the FDA Novel Drug Approvals 2026 list, with the U.S. launch expected in the second half of this year. The pitch is simple: one shot a week instead of seven. For the […]